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Using a case control approach, we performed a two-way comparison study between GP5/6-PCR and HPV
SPF10-Line Blot 25 (SPF10) assays for detection of 14 types of high-risk human papillomavirus (hrHPV) in
samples from women with normal cytology results who had or developed grade 3 cervical intraepithelial
neoplasia (CIN 3). Samples were pooled from two cohorts, i.e., women participating in population-based
screening and women attending a gynecological outpatient clinic. Cases (n  45) were women with histolog-
ically confirmed CIN 3 diagnosed within a median follow-up time of 2.7 (range, 0.2 to 7.9) years. Control
samples were from women (n  264) who had developed CIN 1 lesions at maximum (median follow-up at 5.8
[range, 0 to 10] years). Identical numbers of cases tested positive for 1 or more of the 14 hrHPV types by both
systems (40/45; McNemar; P  1.0). Conversely, SPF10 scored significantly more controls as hrHPV positive
than did GP5/6-PCR (95/264 versus 29/264; McNemar; P < 0.001). Consequently, women with normal
cytology results and an hrHPV GP5/6-PCR-positive test exhibited a risk of CIN 3 that was 4.5 times higher
(odds ratio [OR], 65; 95% confidence interval [95%CI], 24 to 178) than that seen for women with an
hrHPV-positive SPF10 test (OR, 14; 95%CI, 5 to 38)). Similar results were obtained after analysis of both
cohorts separately. Discrepancy analysis by viral load assessment for the most common discordant hrHPV
types (HPV16, -18, and -52) showed that samples which were SPF10 positive only for these types had viral loads
significantly lower than those for samples that were positive by both assays (analysis of variance; P < 0.006).
Our data indicate that GP5/6-PCR has a better clinical performance than SPF10 for women who are
diagnosed with CIN 3 after prior normal cytology results. The extra positivity scored by SPF10 mainly involved
infections characterized by low viral loads that do not result in CIN 3.
Based on the fact that a persistent infection with high-risk
human papillomavirus (hrHPV) is the necessary cause of cer-
vical cancer (4, 20), hrHPV testing has been recognized as a
potentially valuable tool not only for the triage of women with
borderline cytomorphological abnormalities but also for pri-
mary cervical screening, either in conjunction with cytology
testing or not. Support for this comes from various clinical
studies (1, 6, 9, 10, 16, 26). It should be realized, however, that
hrHPV tests might detect both transient and persistent hrHPV
infections, of which only the latter represent a condition that
ultimately may result in the development of grade 3 cervical
intraepithelial neoplasia (CIN 3) lesions and cervical cancer
(CIN 3) and therefore should be considered as clinically
relevant. We previously hypothesized that various hrHPV
tests, although similarly efficient in detecting persistent infec-
tions, may differ considerably in the extent with which tran-
sient, clinically irrelevant hrHPV infections are detected (28).
A clinically valuable hrHPV test should perform in such a
way that the number of transient infections detected is as low
as possible to ensure an optimal balance between clinical sen-
sitivity and specificity for CIN 3. This is important to mini-
mize the number of unnecessary follow-up procedures, partic-
ularly for women with normal cytology results. Based on data
from longitudinal clinical studies involving large cohorts, so far
only the GP5/6-PCR and the commercially available
hrHPV hybrid capture 2 (hc2) assays have been proven to
reach such an optimal balance and therefore can be considered
clinically validated (2, 5, 7, 9, 16, 17, 21, 24). In a previous
two-way comparison study, we showed that these assays, which
both detect hrHPV types as a pool, perform equally well for
the detection ofCIN 3 in a population-based cervical screen-
ing setting (13).
Besides GP5/6-PCR and hc2, the consensus HPV SPF10-
Line Blot 25 linear probe assay (SPF10-LiPA version 1) PCR
assay (15) (referred to herein as SPF10) is a commonly used
HPV detection assay, particularly in epidemiological studies
and vaccination trials (12). However, this method has not yet
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been tested in a comparison study in relation to the occurrence
or development of CIN 3.
We here performed a comparison study between GP5/6-
PCR and SPF10 to detect 14 hrHPV types in samples from
women with normal cytology results who had or developed
CIN 3 lesions. A subsequent discrepancy analysis included viral
load analysis by type-specific real-time PCR.
MATERIALS AND METHODS
Study population. For this case control study, cervical samples used were from
women with normal cytology results who were recruited from 1988 to 1993
during the course of two studies (18, 24) performed in the Amsterdam area and
from whom cervical scrape samples were collected and stored at 80°C. The
study groups comprised women who either participated in a population-based
cervical screening trial (n  4,079) or attended a gynecological outpatient clinic
(n  2,311). Women were managed according to guidelines of the Dutch screen-
ing program. Briefly, women with moderate dyskaryosis or worse (i.e., high-grade
squamous intraepithelial lesions) were directly referred to the gynecologist for
colposcopy. Women with borderline or mild dyskaryosis (i.e., atypical squamous
cells of undetermined significance/low-grade squamous intraepithelial lesions)
were advised to get repeat testing at 6 and 18 months and were referred only in
cases of the persistence of borderline or mildly dyskaryotic changes or when
cytological progression became manifest. Women with normal cytology results
were recalled at the next screening round. Of the population-based screening
cohort, 3,471 women had normal cytology results. Of 2,250 of these women,
sample material and follow-up data were available, and 61 of these women had
a colposcopy-directed biopsy during follow-up. The histological outcomes were
no CIN, CIN 1, CIN 2, and CIN 3 in 8, 22, 6, and 25 of these women, respectively.
Of the remaining 2,189 women, 1,710 had two consecutive cytologically normal
smears at the follow-up. All women with CIN 3 diagnoses were included as cases
in this study, and a random sample of 199 women without evidence of CIN 2/3
upon follow-up (2 with no CIN, 11 with CIN 1, and 186 with two consecutive
normal smears) were included as controls. The median ages of these cases and
controls were 34 (range, 29 to 60) and 41 (range, 34 to 54) years, respectively, and
median follow-up times were 2.1 (range, 1 to 8) and 7.0 (range, 1 to 10) years,
respectively. In this screening cohort, case women were younger than and had a
follow-up time shorter than that of control women (analysis of variance
[ANOVA]; both P values were 0.001).
Of the outpatient clinic cohort, 1,566 women had normal cytology results, and
sample material and follow-up data were available for 1,020 of these women.
Women visited the outpatient clinic for a wide spectrum of gynecological com-
plaints and for their hormonal contraception. One hundred twenty of these
women had a colposcopy-directed biopsy; of these women, 42, 30, 28, and 20
were diagnosed with no CIN, with CIN 1, with CIN 2, and with CIN 3, respec-
tively. All 20 women with CIN 3 in this cohort were included as cases as well, and
all 72 women with a histologically confirmed absence of CIN 2/3 (42 with no CIN
and 30 with CIN 1) were included as controls. The median ages for cases and
controls were 32 (range, 22 to 49) and 37 (range, 20 to 53) years, respectively, and
median follow-up times were 0.2 (range, 0 to 0.5) and 0.3 (range, 0 to 0.6) years.
In the hospital group, ages and follow-up times did not differ significantly be-
tween cases and controls (ANOVA; both P values were 0.05). Taking these
cohorts together, 45 cases and 271 controls were included in this study. Informed
consent was obtained from all participating women, and this study followed the
local ethical guidelines of our medical center.
Cytology results and HPV testing. Cervical scrape specimens were taken from
the cervix uteri with a cervix brush (Rovers, Oss, The Netherlands). A smear was
made on a glass slide for cytomorphological analysis, and the brush with remain-
ing cell material was subsequently placed in a tube containing 5 ml phosphate-
buffered saline–0.05% Merthiolate. Upon arrival in the laboratory, the samples
were spun down and pellets were resuspended in 1 ml Tris-HCl (pH 8) and
stored at 80°C for subsequent HPV analysis. In none of the women were HPV
test results used for triage. Cytomorphological classification was performed as
described before (33).
The high pure PCR template preparation kit was used for DNA extraction
from 100-l Tris-HCl suspensions of stored samples according to the recom-
mendations of the manufacturer (Roche, Mannheim, Germany), except that
samples were eluted with 100 l of elution buffer. Ultimately, 10 l of eluate was
used for each PCR assay. To assess sample quality, DNA isolates were subjected
first to -globin PCR using the primers PCO3/PCO5 (11). The -globin PCR
assay generates a 209-bp PCR fragment, which exceeds the sizes of the PCR
products generated by the SPF10 (about 70 bp) and GP5/6-PCR (about 150
bp) assays. Subsequently, only -globin PCR-positive samples were subjected to
comparative HPV PCR analyses.
The GP5/6-PCR followed by use of the enzyme immunoassay (EIA) read-
out system with a probe cocktail of 14 hrHPV types (i.e., HPV16, -18, -31, -33,
-35, -39, -45, -51, -52, -56, -58, -59, -66, and -68) was performed at the Depart-
ment of Pathology, VU University Medical Center (Amsterdam, The Nether-
lands) as described before (30). Reverse line blotting was used to genotype
hrHPV for all EIA-positive samples (30). HPV testing and genotyping using
HPV SPF10 were performed at the Department of Medical Microbiology, Rad-
boud University Nijmegen Medical Center (Nijmegen, The Netherlands) accord-
ing to a routinely used protocol in which DNA EIA (DEIA) was the first readout
system for SPF10 PCR products with a probe cocktail of 14 of the above-
mentioned hrHPV types plus 24 low-risk HPV types (i.e., 38 types altogether,
including HPV6, -11, -16, -18, -26, -30, -31, -33, -34, -35, -39, -40, -42, -43, -44, -45,
-51, -52, -53, -54, -55, -56, -58, -59, -61, -62, -64, -66, -67, -68, -69, -70, -72, -73, -74,
-82 [MM4], MM7, and MM8) (15, 32). DEIA-positive samples were subse-
quently subjected to LiPA typing. Both GP5/6-PCR and SPF10 assays target
the L1 region in the HPV genome. Testing with both methods was performed in
parallel by different technicians who were unaware of each others’ test results
and were blinded to the case/control status of the samples.
For final analysis, the GP5/6-PCR and SPF10 assays were considered
hrHPV positive when reverse line blotting and LiPA genotyping, respectively,
revealed 1 or more of the 14 abovementioned hrHPV genotypes that can be
detected by (D)EIA of both assays. Samples that showed a positive (D)EIA
signal but failed to reveal a positive signal in the subsequent typing assays were
designated as containing HPV-X, which may indicate (sub)types and/or variants
that were not available on the respective typing blots. Genotyping results were
considered concordant if there was complete agreement between both assays for
1 or more of the 14 hrHPV types listed above. Results were considered com-
patible when at least one type was detected with both assays while one or more
other types were not detected by either of the assays. Genotyping data were
considered discordant when no similarity between genotypes detected by both
assays was found.
Viral load analysis. Viral load analysis was performed by type-specific real-
time PCR for HPV16, -18, and -52 on the LightCycler instrument essentially as
described before (14, 27). Real-time PCR was performed on 5 l of DNA isolate,
representing about 1/200 of the DNA of the total scrape specimen. Primers and
probes used for HPV16 and -18 real-time PCR have been described before (14,
27). The oligonucleotide sequences for primers and probes used for HPV52
real-time PCR were as follows: the forward primer was 5-ATGGACAAGCAG
AACAAGCCA-3 (nucleotide [nt] positions 683 to 704); the reverse primer was
5-CCCTCCCTTTCGCCCTCT-3 (nt positions 884 to 902); the donor probe
was 5-TGCGACGGACCTTCGTACTCTACAGC-3 (nt positions 773 to 799),
with the 3 end labeled with fluorescein; and the acceptor probe was 5-TGCT
GTTGGGCACATTACAAGTTGTG-3 (nt positions 803 to 828), with the 5
labeled with LCRed640. Viral loads were expressed as HPV DNA copies per
scrape specimen.
Statistical analysis. Positivity rates for the GP5/6-PCR and SPF10 assays of
cases and controls were calculated, and Mantel-Haenszel common odds ratios
(ORs) were computed to study assay positivity in relation to the development of
CIN 3. The sensitivities, specificities, and ORs were relative to the procedure.
The McNemar test was used for mutual comparison of the positivity rates of the
GP5/6-PCR and SPF10 assays in the two subgroups, i.e., cases and controls.
Both pooled and separate analyses of cases and controls of both cohorts were
performed. The level of agreement was determined using kappa statistics. All
HPV viral load values were log normalized. One-way ANOVA was used to
compare viral loads between the GP5/6-PCR-negative/SPF10-positive group
and the GP5/6-PCR-positive/SPF10-positive group. GP5/6-PCR- and/or
SPF10-positive samples that were negative in the LightCycler tests, thus contain-
ing numbers of HPV copies below the detection level, were set at 10 copies (3,
14), which corresponds to approximately 2,000 copies per scrape specimen. The
level of statistical significance was set at 0.05. All analyses were performed using
SPSS 11.5 software.
RESULTS
Clinical performance of hrHPV detection by GP5/6-PCR
and SPF10 assays. A case control design was used in order to
compare the clinical performances of GP5/6-PCR and
SPF10 assays for the identification of women with normal cy-
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tology results who had developed CIN 3. A total of 45 cases
(women with CIN 3 diagnosed within a median follow-up time
of 2.7 [range, 0 to 8] years) were pooled from two different
cohorts (18, 24) of women participating in population-based
cervical screening (n  25) and women visiting a gynecological
outpatient clinic (n  20), respectively. A random sample of
271 controls (199 from the screening population and 72 from
the hospital population) involved women without evidence of
CIN 2/3 within a median follow-up time of 5.8 (range, 0 to 10)
years.
-Globin PCR analysis of extracted DNA revealed positivity
for samples of all cases and 264 controls (193 and 71 of screen-
ing and hospital populations, respectively), and these were
considered valid for further HPV PCR analyses. Both HPV
PCR assays were subsequently performed on equal amounts of
the same DNA isolates of -globin PCR-positive samples. Af-
ter (D)EIA detection using cocktail probes, GP5/6-PCR
gave positive results for 71 samples (42/45 cases and 29/264
controls) and SPF10 for 171 samples (42/45 cases and 129/264
controls). However, it should be noted that whereas the cock-
tail probe for GP5/6-PCR EIA detects only 14 hrHPV
types (i.e., HPV16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58,
-59, -66, and -68), that of SPF10 detects 24 additional low-risk
HPV types as well. Subsequent genotyping by the respective
reverse hybridization methods revealed that 2 of the 71 GP5/
6-PCR EIA-positive samples and 36 of the 171 SPF10 DEIA-
positive samples did not show a positive typing result for 1 or
more of the 14 hrHPV types. These included 2 cases with
positivity by both GP5/6-PCR and SPF10 and an additional
34 controls with positivity by SPF10 only. Both of the GP5/
6-PCR EIA-positive, typing-negative cases could be identi-
fied as containing HPV-X, whereas one SPF10 DEIA-positive
case contained HPV-X and another HPV6. Of the 34 SPF10
DEIA-positive, typing-negative controls, 24 contained low-risk
HPV and 10 HPV-X.
The data obtained after restricting the analysis to the 14
hrHPV types are summarized in Table 1. Overall, the GP5/
6-PCR assay scored a significantly low number of samples as
hrHPV positive (n  69) compared to the SPF10 assay (n 
135; McNemar; P  0.001). Restricting the analysis to cases,
the hrHPV positivity rates of the GP5/6-PCR and SPF10
assays were similarly high, namely, 89% (40/45; 95% confi-
dence interval [95%CI], 80 to 98), and did not significantly
differ (McNemar; P  1.0). Similar results were obtained after
analysis of samples from case women from both cohorts sep-
arately (Table 1). The assays scored 88% (22/25; 95%CI, 76 to
100) and 90% (18/20; 95%CI, 77 to 100) of samples from case
women from the screening and hospital cohorts, respectively,
as hrHPV positive.
The overall higher hrHPV positivity of the SPF10 assay was
due to a significantly high hrHPV positivity rate for control
women (36%; 95/264; 95%CI, 31 to 43) compared to that
obtained by the GP5/6-PCR assay (11%; 29/264; 95%CI, 7
to 15) (McNemar; P  0.001). The difference between both
assays was evident for samples of control women of both co-
horts (Table 1). For the screening cohort, the hrHPV positivity
TABLE 1. Test results for 14 hrHPV types by GP5/6-PCR and SPF10 assays for samples from women with normal cytology results
Sample group GP5/6-PCRresult
No. (%) with indicated result by
SPF10 assay Total (%) P valuea
Negative Positive
Overall
Controls Negative 163 (62) 72 (27) 235 (89) 0.001
Positive 6 (2) 23 (9) 29 (11)
Total 169 (64) 95 (36) 264
Cases Negative 4 (9) 1 (2) 5 (11) 1.0
Positive 1 (2) 39 (87) 40 (89)
Total 5 (11) 40 (89) 45
Screening cohort
Controls Negative 127 (66) 53 (27) 180 (93) 0.001
Positive 4 (2) 9 (5) 13 (7)
Total 131 (68) 62 (32) 193
Cases Negative 2 (8) 1 (4) 3 (12) 1.0
Positive 1 (4) 21 (84) 22 (88)
Total 3 (12) 22 (88) 25
Hospital cohort
Controls Negative 36 (51) 19 (27) 55 (77) 0.001
Positive 2 (3) 14 (20) 16 (23)
Total 38 (54) 33 (46) 71
Cases Negative 2 (10) 0 2 (10) 1.0
Positive 0 18 (90) 18 (90)
Total 2 (10) 18 (90) 20
a McNemar.
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of the SPF10 versus the GP5/6-PCR assay was 32% (62/193;
95%CI, 25 to 39) versus 7% (13/193; 95%CI, 3 to 11). For the
hospital cohort, the corresponding figures were 46% (33/71;
95%CI, 34 to 58) versus 23% (16/71; 95%CI, 13 to 33). For
both cohorts, these differences were statistically significant
(McNemar; P  0.001).
The strength of the overall agreement in assay positivity was
moderate (kappa values of 0.42). When stratification was done
according to cases and controls, this strength was poor for
controls (kappa value of 0.24) but good for cases (kappa value
of 0.78). The significantly high positivity rate for controls as-
sayed by SPF10 compared to that assayed by GP5/6-PCR
was reflected in the ORs of both assays for CIN 3. The overall
ORs (Mantel-Haenszel) were 14 (95%CI, 5 to 38; P  0.001)
for the SPF10 assay and 65 (95%CI, 24178; P  0.001) for the
GP5/6-PCR assay. This indicates that women with normal
cytology results who tested hrHPV positive by the GP5/6-
PCR assay were 4.5 times more likely to have or develop CIN
3 lesions than those who were hrHPV positive by the SPF10
assay. The agreement figures and differences in ORs did not
differ meaningfully when calculated for the two cohorts sepa-
rately (data not shown).
Comparison of hrHPV genotypes detected by the GP5/6-
PCR and SPF10 assays. As specified in Table 2, the samples
that were scored as hrHPV positive by the SPF10 assay but
negative by the GP5/6-PCR assay displayed a broad variety
of hrHPV genotypes, although HPV52 infections were rela-
tively frequent. Among 23 control samples that were hrHPV
positive by both assays, 17 (74%) showed concordant, 2 (9%)
compatible, and 4 (17%) discordant typing results. For case
samples, these numbers were 31 (79%), 7 (18%), and 1 (3%),
respectively. Thus, one or more of the same hrHPV types were
detected by both assays in 83% of the control samples and 97%
of the case samples that were positive by both assays. The
single discordant case had HPV16 as determined by the GP5/
6-PCR assay and HPV52 according to the SPF10 assay. Fur-
thermore, one case sample that was hrHPV negative by the
SPF10 assay was positive for HPV16 by the GP5/6-PCR
assay, and one case sample that was negative for hrHPV by the
GP5/6-PCR assay contained HPV52 according to the
SPF10 assay.
Analysis of discordant GP5/6-PCR and SPF10 test re-
sults. To investigate whether the nondetection of hrHPV by
the GP5/6-PCR assay in samples positive by the SPF10
assay might be due to low viral loads, we determined the
type-specific viral loads of three types (HPV16, -18, and -52 in
both single and multiple infections) that most commonly re-
vealed discordant typing results. For this purpose, we tested a
total of 56 cervical scrape specimens of which sufficient sample
material was left for real-time PCR. These included samples of
case and control women with both discordant (13 for HPV16,
14 for HPV18, and 15 for HPV52) and concordant (6 for
HPV16 and 4 for both HPV18 and HPV52) SPF10 and GP5/
6-PCR test results. The median HPV16, -18, and -52 DNA
loads for the GP5/6-PCR assay-negative but SPF10 assay-
positive group were 7.0 	 103 (range, 2.0 	 103 to 4.4 	 104),
2.0	 103 (range, 2.0	 103 to 4.8	 104), and 2.0	 103 (range,
2.0 	 103 to 2.1 	 108) HPV copies/scrape specimen, respec-
tively, and were significantly lower (ANOVA; all P values were
0.006) than those for the GP5/6-PCR assay-positive/
SPF10 assay-positive group, i.e., 1.1 	 10
6 (range, 1.6 	 105 to
7.7	 106), 7.4	 107 (range, 4.0	 105 to 8.0	 107), and 3.7	
106 (range, 2.4 	 105 to 3.7 	 106), respectively (Fig. 1). Only
three samples that were HPV52 positive by the SPF10 assay
and GP5/6-PCR assay negative had viral load levels that
overlapped with those of SPF10 and GP5/6-PCR assay dou-
ble-positive samples for this type. These samples, all from
control women, might contain certain HPV52 variants that are
less efficiently detected by the GP5/6-PCR assay than by
the SPF10 assay (8). The viral load of the CIN 3 case missed by
the GP5/6-PCR assay, which was positive for HPV52 by the
SPF10 assay, revealed 1.0 	 10
4 copies/scrape specimen. After
the restriction of calculations to control samples, only for
HPV16 were sufficient samples with concordant GP5/6-
PCR and SPF10 results available. This analysis revealed similar
findings. Thus, the exclusion of cases had no influence on the
relation between lower viral loads and GP5/6-PCR assay-
negative but SPF10 assay-positive samples (ANOVA; P 
0.001; data not shown). Altogether, these data indicate that the
extra positivity scored by the SPF10 assay in relation to the
GP5/6-PCR assay mainly involved relatively low viral
loads.
DISCUSSION
Comparison of the clinical performances of hrHPV detec-
tion by the GP5/6-PCR and SPF10 assays showed that both
assays had similar overall clinical sensitivities (i.e., 89%) for
the prediction of finding CIN 3 lesions (i.e., via detection of
hrHPV) in women with cytomorphologically normal smears. It
is of note that the actual overall sensitivity values of these
assays would be slightly higher (i.e., 93% [95%CI, 86 to 100]
for the GP5/6-PCR assay and 91% [95%CI, 83 to 99] for
the SPF10 assay) in this set when the outcome is based on
hrHPV detection using a pool by (D)EIA, since two GP5/
6-PCR EIA-positive cases and one SPF10 DEIA-positive
case were designated as HPV-X and were not included in the
final analysis. In practice, in clinical and experimental screen-
ing settings, scoring of hrHPV GP5/6-PCR assay positivity
is based on the EIA readout only, showing a good sensitivity (2,
5–7). The positivity rate in controls was significantly low for the
GP5/6-PCR assay compared to that for the SPF10 assay.
The latter could be attributed mainly to the fact that SPF10
scored as positive significantly more samples from control
women that had viral load levels apparently falling below the
detection level of the GP5/6-PCR assays. Consequently,
women with normal cytology results and a GP5/6-PCR-
positive test result exhibited a 4.5 times higher risk of CIN 3
than those with a positive SPF10 test result. Altogether, these
data confirm our previous concept (28) that a too-high analyt-
ical sensitivity of an hrHPV test results in a marked decrease in
clinical specificity without having an impact on the clinical
sensitivity for detecting the ultimate development of CIN 3.
This is in line with data from several studies indicating that not
hrHPV DNA presence per se but increased viral loads confer
an increased risk of CIN 3 (19, 27, 31, 34).
It is noteworthy that differences in the population charac-
teristics could influence the relative performance of each assay.
However, in this study similar differences in assay performance
were found for control women of both the screening and the
3218 HESSELINK ET AL. J. CLIN. MICROBIOL.
 o
n
 July 13, 2012 by Universiteitsbibliotheek
http://jcm.asm.org/
D
ow
nloaded from
 
gynecological outpatient populations. The fact that among the
first group of women the median age was significantly higher
for controls (i.e., 41 years) than for cases (i.e., 34 years) is
unlikely to have contributed markedly to the observed differ-
ence between both assays, since in the hospital population the
median ages of cases and controls (32 versus 37 years) did not
differ significantly. Our data nevertheless seem to contradict
those found in a study reported by Safaeian et al. (25). That
study revealed that for women with normal cytology results
enrolled for a vaccination trial, there was no difference in
hrHPV positivities between the SPF10 and hc2 assays, the
latter of which is considered to be compatible with the GP5/
6-PCR assay (25). A likely explanation for this apparent
discrepancy is that Safaeian et al. studied young women under
30 years of age (median age, 21 years; range, 18 to 25 years). It
is therefore tempting to speculate that hrHPV positivity in
women under 30 years of age with normal cytology results is
often accompanied by relatively high viral loads, giving rise to
TABLE 2. HPV genotyping results for 14 hrHPV types of SPF10 versus GP5/6-PCR
hrHPV type by
SPF10 assay
No. of samples of indicated type
Concordant Compatible(genotype by GP5/6-PCR assay)
Discordant (genotype by
GP5/6-PCR assay )
hrHPV negative
by GP5/6-PCR assay
Control sample type(s)
None 6 (3 of type 31, 1 of 39, 163
16 3 2 of 16, 1 of 18) 10
18 8
31 2 5
33 2 3
35 1 (45) 1
39 1 4
45 1
51 1 1 (16, 18, 39) 5
52 3 12
56 1 4
58 1 (31)
59 1 (56, 59)
66 3 1
68 1
16,18 1 8
16, 18, 66 1
16, 31 1
16, 39, 52 1
16, 68 1
18, 31 1
18, 39 1 (16)
18, 52 1
31, 52 1
35, 39 1
52, 56 1
51, 52, 56 1 (45, 56)
Total 17 2 10 235
Case sample type(s)
None 1 (16) 4
16 11 1 (16, 58)
18 3 1 (18, 31)
31 5
33 2
35 3
39 1
45 1 (18, 45)
51 1
52 1(52, 56) 1 (16) 1
56 1
59 1
16, 18 1
16, 31 1
16, 52 1 (16)
18, 33 1 (18)
31, 51 1
39, 52, 68 1 (39, 52)
Total 31 7 2 5
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positivity rates that are equal for assays displaying different
analytical sensitivities for hrHPV. This is supported by findings
of a different comparison study between SPF10 and hc2 on
samples from a population of women visiting a colposcopic
clinic (22). The latter study mainly included women above 30
years of age and displayed for women with normal cytology
results a difference between hrHPV positivity by SPF10 versus
that by hc2 that was similar to that seen for SPF10 versus
GP5/6-PCR assays for control samples from our study.
Taken together, these data indicate that the threshold for
the positivity of a given hrHPV test should be at such a level
that an optimal balance between clinical sensitivity and speci-
ficity for identifying women at risk of having or developing
CIN 3 is reached. This concept finds support by recent rec-
ommendations of the American Society for Colposcopy and
Cervical Pathology (ASCCP) (29), which indicate that in a
cervical screening setting, clinical sensitivities for CIN 3 of at
least 92% 
 3% seem satisfactory only when clinical specific-
ities are above 85% at the same time. Therefore, the GP5/
6-PCR assay can be advocated above SPF10 for screening
purposes involving women over 30 years of age.
Apart from the difference in clinical performances, both
tests showed common characteristics, since there was a high
concordance in hrHPV genotyping, especially for samples
from case women. We found a relatively high number of in-
fections with HPV52 among the women for whom samples
were SPF10 positive and GP5/6-PCR negative. This cannot
be explained solely by a potentially low sensitivity of the
GP5/6-PCR assay for HPV52 compared to that for HPV16
and HPV18 (23). The minimal HPV52 viral load value deter-
mined for SPF10 assay-positive but GP5/6-PCR assay-neg-
ative samples did not differ markedly from those for HPV16
and -18. In fact, only three discordant HPV52 control samples
might have resulted from a lower detectability by the GP5/
6-PCR assay, possibly because these infections involve
HPV52 variants. Thus, the majority of HPV52 infections de-
tected by the SPF10 assay alone are due to lower copy numbers
of HPV52, which are apparently relatively common among
SPF10-positive women with normal cytology results.
In conclusion, the application of hrHPV detection assays
with a too-high analytical sensitivity for hrHPV results in a
markedly reduced specificity for CIN 3 without being beneficial
for clinical sensitivity. Therefore, hrHPV test requirements, as
currently under preparation in The Netherlands, should be
incorporated in cervical screening guidelines to prevent over-
detection, which would counteract the benefits of implement-
ing hrHPV testing in screening programs.
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